Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
5.67 USD +1.07% Intraday chart for TELA Bio, Inc. +5.98% -14.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating MT
Transcript : TELA Bio, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $17M, vs. Street Est of $16.4M MT
TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2024 CI
TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product MT
MiMedx Group, Inc. Enters into an Agreement with Tela Bio, Inc. to Obtain Exclusive Rights to Its Manufacturing and Supply Agreement CI
Transcript : TELA Bio, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (TELA) TELA BIO Posts Q3 Revenue $15.1M, vs. Street Est of $16.2M MT
TELA Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc CI
Advanced Medical to commercialise LiquiBandFix8 in US under Tela deal AN
Advanced Medical Solutions Partners with Tela Bio for US Commercialization of Surgical Device MT
Advanced Medical Solutions Group plc Signs Agreement with TELA Bio, Inc CI
TELA Bio, Inc.(NasdaqGM:TELA) added to S&P Global BMI Index CI
TELA Bio Launches OviTex Product to Support Implants in Plastic, Reconstructive Surgery MT
TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery CI
Transcript : TELA Bio, Inc., Q2 2023 Earnings Call, Aug 09, 2023
Earnings Flash (TELA) TELA BIO Posts Q2 Revenue $14.5M, vs. Street Est of $14.4M MT
TELA Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023 CI
Certain Warrants of TELA Bio, Inc. are subject to a Lock-Up Agreement Ending on 18-JUL-2023. CI
Certain Restricted Stock Units of TELA Bio, Inc. are subject to a Lock-Up Agreement Ending on 18-JUL-2023. CI
Certain Options of TELA Bio, Inc. are subject to a Lock-Up Agreement Ending on 18-JUL-2023. CI
Chart TELA Bio, Inc.
More charts
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.67 USD
Average target price
14.6 USD
Spread / Average Target
+157.50%
Consensus
  1. Stock
  2. Equities
  3. Stock TELA Bio, Inc. - Nasdaq
  4. News TELA Bio, Inc.
  5. TELA Bio Enters Into New $50 Million Credit Facility With MidCap Financial